Longer observational periods with larger cohorts are needed to further elucidate the role of GLP-1-RAs in treating IIH
By engaging GIP , GLP-1 , and glucagon pathways at the same time, the compound allows researchers to study how these systems work together to regulate appetite control, insulin-related signaling, and overall energy use
In vitro assays show that retatrutide demonstrates enhanced potency at the human GIPR compared to natural GIP
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
As the discontinuation rates were also high with the twice daily danuglipron at the phase 2 obesity trial (as discussed above), twice daily danuglirpon formulation will not advance into phase 3 studies, but an improved once-daily formulation with an aim to improve tolerability profile is currently under assessment [27]
